Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and safety. To address this challenge, researchers have developed the first ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on ...

Explore our comprehensive live blog on AMD's CES 2025 Keynote, detailing the latest Ryzen and Radeon releases and innovations ...

While all eyes are on NVIDIA for its RTX 5000 GPUs at CES 2025, AMD is also taking the opportunity to give us a glimpse at ...

I recently watched an episode of one of my favourite TV shows, the Good Doctor. The episode revolved around how a man named Wyatt was rushed into the ER as he had a perforated valve and needed ...

It is hard to overestimate the importance of antibodies in the frameworks of biotechnology and pharmaceutical industries.

Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Myelodysplastic Syndrome.

Thanks to all the leaks, I thought I knew what to expect with AMD’s upcoming RDNA 4. It turns out I may have been wrong on more than one account. The latest leaks reveal that AMD’s upcoming ...